Cost effectiveness was assessed by comparing incremental cost-effectiveness ratios against $100,000 per QALY, with strategies considered "cost-effective" when their ratios (vs the next least costly alternative) remained below this limit
Long-term effects of tirzepatide may include more severe issues
Canadian Patents Database notes the status as: Expired and beyond the Period of Reversal. In the U.S., Novo Nordisk said in its 2025 Form 20-F that U.S
It belongs to a novel class of agents known as triple agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
I'd like to share my great experience at VitalityMD
Nearly two-thirds of participants on Tirzepatide lost at least 20% of their baseline weight, a magnitude not previously seen with GLP-1only therapy (Jastreboff, New England Journal of Medicine )